Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR10899987

—

3ea23954-2ba2-5987-a290-1f25e6777689

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.500
  • APICAL_SURFACE+0.500
  • ESTROGEN_RESPONSE_EARLY+0.400
  • INFLAMMATORY_RESPONSE+0.400
  • INTERFERON_ALPHA_RESPONSE+0.400
  • INTERFERON_GAMMA_RESPONSE+0.400
  • KRAS_SIGNALING_UP+0.400
  • TNFA_SIGNALING_VIA_NFKB+0.400
  • APICAL_JUNCTION+0.300
  • COAGULATION+0.300

Top 10 suppressed

  • E2F_TARGETS-0.600
  • MYC_TARGETS_V2-0.600
  • G2M_CHECKPOINT-0.500
  • MYC_TARGETS_V1-0.500
  • OXIDATIVE_PHOSPHORYLATION-0.500
  • DNA_REPAIR-0.400
  • MTORC1_SIGNALING-0.400
  • UNFOLDED_PROTEIN_RESPONSE-0.400
  • GLYCOLYSIS-0.300
  • PROTEIN_SECRETION-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BS_Z28VKGNS
brain-umap@2
Neurofibroma—0.937
2s0102868
melanoma-umap@29
——0.936
3a802b49c.736d.427c.bcca.8375c4171284
lung-landscapes@6
—cohortA10.921
4TCGA-CV-6943-01A-11R-1915-07
head-neck@1
——0.918
5TCGA-38-7271-01A-11R-2039-07
lung-landscapes@6
—cohortMD20.917
6BS_FQX1PRAJ
brain-umap@2
Neurofibroma—0.916
7TCGA-22-1000-01A-01R-A32Z-07
lung-landscapes@6
—cohortSQ10.916
8TCGA-D8-A73U-01A-11R-A33J-07
breast-umap@18
—D0.915
9MDT-AP-3282
medullo-epn-umap@date-based
MedMedulloblastoma0.914
10sclcA055A_S52.txt
lung-landscapes@6
—cohortMD20.913

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 27 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.500Idelalisib— uncovered
APICAL_SURFACE0.500Temsirolimus— uncovered
ESTROGEN_RESPONSE_EARLY0.400Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.400Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.400Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.400Idelalisib— uncovered
KRAS_SIGNALING_UP0.400Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.400Inavolisib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
COAGULATION0.300Binimetinib— uncovered
COMPLEMENT0.300Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.300Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.300Idelalisib— uncovered
IL2_STAT5_SIGNALING0.300Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.300Inavolisib— uncovered
NOTCH_SIGNALING0.300Inavolisib— uncovered
UV_RESPONSE_DN0.300Inavolisib— uncovered
KRAS_SIGNALING_DN0.200Remibrutinib— uncovered
P53_PATHWAY0.200Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.200Inavolisib— uncovered